LIVSMED soars to limit up...PharmAbcine delists at 115 won [K-Bio Pulse]

[Lim Jeong-yeo, Edaily Reporter] On the 26th, as the KOSDAQ index broke above 1,000 for the first time in four years, the domestic pharmaceutical and biotech stock market saw LIVSMED hitting the daily upper limit.

On the same day, PharmAbcine, often referred to as South Korea's first generation biotech venture, saw its corporate value plunge on the stock market on the final day of trading prior to delisting.

LIVSMED chart(Cred=KG Zeroin MP Doctor) ◇LIVSMED takes flight as overhang concerns dissipate According to KG Zeroin MP Doctor (formerly Market Point), LIVSMED closed at 80,800 won on the day, up 29.90% (18,600 won) from the previous session.